trending Market Intelligence /marketintelligence/en/news-insights/trending/g_MqDYN-smJ_-xoc5R47ew2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Orexigen considering potential sale as it may not meet debt terms

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Orexigen considering potential sale as it may not meet debt terms

Orexigen Therapeutics Inc. said in a SEC filing that it is evaluating whether it can continue as a "going concern," as it might not be able to meet its debt obligations due in 2018.

As part of steps the biotech company may take to meet "possible liquidity requirements," it is looking at getting additional funds, negotiating with note holders and trying to pursue talks for a sale or merger.

The company needs to be able to meet a term under its debt agreement that allows holders of its 0% convertible senior secured notes due 2020, to redeem their notes after June 30, 2018, if the company's total sales for fiscal 2017 drop below $100 million.

Orexigen expects total revenues for the third quarter of 2017 to be between about $18.1 million and $19.1 million.

Meanwhile, the company will continue to have market exclusivity for its lead product Contrave until 2030, after it recently prevailed in a patent litigation lawsuit against Actavis Laboratories FL Inc.